Pfizer Appoints David M. Denton as Chief Financial Officer and Executive Vice President

On April 11, Pfizer announced that David M. Denton will assume the role of Chief Financial Officer (CFO) and Executive Vice President of the company on May 2, 2022, reporting directly to Chairman and Chief Executive Officer Albert Bourla. Former CFO Frank D’Amelio will retire soon after serving at Pfizer for 15 years.

Denton has over 25 years of experience in finance and operations, including more than 20 years in the healthcare industry. Before joining Pfizer, Denton served as CFO and Executive Vice President at Lowe’s Companies. Additionally, he held the roles of CFO and Executive Vice President at CVS Health, where he was responsible for corporate financial planning and management. In December 2017, Denton played a key role in the acquisition of Aetna by CVS, structuring and negotiating the terms and financing of the deal.

In 2021, Pfizer's total revenue reached 81.288 billion U.S. dollars, increasing by 95% year-on-year, of which the income from the COVID-19 vaccine Comirnaty was 36.78 billion U.S. dollars. With the addition of the COVID-19 oral drug Paxlovid, Pfizer's revenue in 2022 is expected to exceed 100 billion U.S. dollars. During this prosperous period, Denton joined Pfizer. It is expected that under his leadership, Pfizer will make further progress.